Supplemental Figure S1



Fig S1. Flow cytometry analysis of splenocytes and peritoneal cavity (PC) cells from *p53*$^{-/-}$ mice without *TCL1*-Tg at 4-month old of age. The splenocytes and PC cells from three mice were analyzed, and representative flow cytometry plots are shown. The number in each panel shows the % of CD5+/IgM+ cells.

Supplemental Figure S2



Fig S2. Flow cytometry analysis of bone marrow cells from age-match (7 month) *TCL1*-Tg and *TCL1*-Tg:p53$^{+/-}$mice. A. Representative flow cytometry plots. The number in each panel shows the % of CD5+/IgM+ cells. B. Bar graph showing the mean and standard deviation of the percentage of CD5+/IgM+ cells in the bone marrow of *TCL1*-Tg and *TCL1*-Tg:p53$^{+/-}$ mice (n =4 per group); the symbol "O" indicates CD5+/IgM+ cells undetectable in *TCL1*-Tg mice. T*CL1*-Tg:p53$^{-/-}$ mice died before 7 month and no bone marrow data is available for the 7-month time point.

Supplemental Figure S3



Fig S3. Flow cytometry analysis of drug-induced cell death in purified CD19+ CLL Cells isolated from CLL patient blood samples without 17p deletion (patients #1-3, wt) or with 17p deletion (#4-6, 17p-). Purified CLL cells were treated with 10 µM F-ara-A or 10 µM Oxaliplatin for 48h, and cell viability was measured by annexin V/PI double staining. The number in each panel shows % of viable cells. The bar graph on the right side shows the mean ± SD of 3 patient samples, *, $p<0.05$ compared to the control.

Supplemental Figure S4



Fig S4. Expression of Bcl-2 family members in purified CD19+ CLL cells isolated from the blood samples of CLL patients with or without 17p deletion. (A) Protein expression of the Bcl-2 family members assayed by western blot analysis. (B) mRNA expression of the Bcl-2 family members measured by real time RT-PCR. *, $p<0.05$ comparing CLL cells with 17p deletion to that without 17p deletion.